Cochrane · systematic review · CD012756
Bisphosphonate use in children with cerebral palsy
Hurley, T, Zareen, Z, Stewart, P, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Developmental, Psychosocial and Learning ProblemsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 3 · 50%Very low 3 · 50%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Bisphosphonate treatment (oral or intravenous) compared to placebo or no treatment for children under the age of 18 with cerebral palsy (GMFCS levels III to V)
Population: children under the age of 18 with cerebral palsy (GMFCS levels III to V)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in BMD lumbar spine (%, assessed at 6 months post‐intervention) Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment | no estimate extracted | 1 study · 12 participants | Very low Downgraded: risk of bias, imprecision |
Change in volumetric BMD of distal radius or tibia Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment | no estimate extracted | 0 studies · 0 participants | Ungraded |
Change in fracture frequency Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse events (ongoing reporting, up to 6 months post‐intervention) Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment | no estimate extracted | 1 study · 12 participants | Ungraded |
Change in NTX (assessed 4 to 6 months post‐intervention) Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment | no estimate extracted | 2 studies · 32 participants | Very low Downgraded: risk of bias, imprecision |
Change in BAP (assessed 4 to 6 months post‐intervention) Bisphosphonate treatment (oral or intravenous) vs placebo or no treatment | no estimate extracted | 2 studies · 32 participants | Very low Downgraded: risk of bias, imprecision |